Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of sequential docetaxel + cisplatin followed by gemcitabine in advanced non-small-cell lung cancer
2004-001044-72Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, cisplatin, gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jan 2007; status: completed.
02
Drugs
docetaxelcisplatingemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-001044-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001044-72.